Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Pancreatic Fistula 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Hypoglycemia 1Gastro-enteropancreatic neuroendocrine tumor 1Dumping Syndrome 1Acromegaly 1

Interventions

Nivolumab 5aldesleukin 3Ipilimumab 3Blood Specimen Collection 3relatlimab 2Vemurafenib 2Immune Checkpoint Inhibitors 2trametinib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1sargramostim 1pembrolizumab 1pasireotide 1encorafenib 1dabrafenib 1binimetinib 1Vindesine 1Standard of Care 1Specimen Handling 1Sevoflurane 1Propofol 1Pharmaceutical Preparations 1Patient-Specific Modeling 1Isoflurane 1Interleukins 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fibrin Tissue Adhesive 1Etanercept 1Desflurane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Melanoma × pasireotide × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡